A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19)
Author:
Affiliation:
1. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland;
2. Edge BioInnovation Consulting, Frederick, Maryland
Publisher
American Society of Tropical Medicine and Hygiene
Subject
Virology,Infectious Diseases,Parasitology
Reference23 articles.
1. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);Yao;Clin Infect Dis,2020
2. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro;Weston,2020
3. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model;Dowall;J Gen Virol,2015
4. On chikungunya acute infection and chloroquine treatment;De Lamballerie;Vector Borne Zoonotic Dis,2008
5. Chloroquine for influenza prevention: a randomized, double-blind, placebo controlled trial;Paton;Lancet Infect Dis,2011
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV‐2 infection and prevention of COVID‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial;Acta Obstetricia et Gynecologica Scandinavica;2023-12-14
2. Converting a drug from off‐label to on‐label use: Government subsidies and patient welfare;Decision Sciences;2022-06-20
3. COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype;Mini-Reviews in Organic Chemistry;2022-06
4. Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review;Pharmaceuticals;2022-05-21
5. Roles of existing drug and drug targets for COVID-19 management;Metabolism Open;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3